Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Alexion Pharmaceuticals fell $2.20 (-2.0%) to $107.56 on heavy volume. Throughout the day, 2,629,472 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,584,700 shares. The stock ranged in price between $105.32-$110.88 after having opened the day at $107.87 as compared to the previous trading day's close of $109.76. Other companies within the Drugs industry that declined today were:
), down 29.6%,
), down 20.9%,
), down 14.2% and
), down 13.0%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $21.4 billion and is part of the health care sector. Shares are up 16.7% year to date as of the close of trading on Wednesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Alexion Pharmaceuticals Ratings Report.
On the positive front,
), up 15.2%,
), up 11.6%,
), up 9.0% and
), up 7.8% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.